1-Arylpiperazinyl-4-cyclohexylamine derived isoindole-1,3-diones as potent and selective α-1a/1d adrenergic receptor ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 6, 2007, Pages 1646-1650

  Li, Shengjian ^a   Chiu, George ^a   Pulito, Virginia L ^a   Liu, Jingchun ^a   Connolly, Peter J ^a   Middleton, Steven A ^a  

^a Drug Discovery Raritan   (United States)

Author keywords

Adrenergic receptor antagonists

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; CYCLOHEXYLAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; RO 70004; TAMSULOSIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; LOWER URINARY TRACT SYMPTOM; PROSTATE HYPERTROPHY;

ADRENERGIC ALPHA-ANTAGONISTS; INDICATORS AND REAGENTS; INDOLES; KINETICS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; PIPERAZINES; RADIOPHARMACEUTICALS; RECEPTORS, ADRENERGIC, ALPHA-1; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TETRALONES;

EID: 33847066217     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.12.111     Document Type: Article

References (29)

1. Caine M. J. Urol. 136 (1986) 1
2. Harrison J.K., Pearson W.R., and Lynch K.R. Trends Pharmacol. Sci. 12 (1991) 62
3. Betti L., Botta M., Corelli F., Floridi M., Giannaccini G., Maccari L., Manetti F., Strappaghetti G., Tafi A., and Corsano S. J. Med. Chem. 45 (2002) 3603
4. Morrow A.L., and Creese I. Mol. Pharmacol. 29 (1986) 321
5. Minneman K.P., Han C., and Abel P.W. Mol. Pharmacol. 33 (1988) 509
6. Schwinn D.A., Lomasney J.W., Lorenz W., Szklut P.J., Fremeau Jr. R.T., Yang-Feng T.L., Caron M.G., Lefkowitz R.J., and Cotecchia S. J. Biol. Chem. 265 (1990) 8183
7. Ramarao C.S., Denker J.M.K., Perez D.M., Gaivin R.J., Riek R.P., and Graham R.M. J. Biol. Chem. 267 (1992) 21936
8. Bruno J.F., Whittaker J., Song J., and Berelowitz M. Biochem. Biophys. Res. Commun. 179 (1991) 1485
9. Veronneau-Longueville F., Rampin O., Jardin A., Benoit G., and Giuliano F. Int. Impot. Res: Official J. Int. Soc. Impot. Res. 10 (1998) 187
10. Walden P.D., Drukin M.M., Lepor H., Wetzel J.M., Gluchowski C., and Gustafon E.L. J. Urol. 157 (1997) 1032
11. Malloy B.J., Price D.T., Price R.R., Bienstock A.M., Dole M.K., Funk B.L., Rudner X.L., Richardson C.D., Donatucci C.F., and Schwinn D.A. J. Urol. 160 (1998) 937
12. Blue, D. R. Jr; Grino, P. B.; Jung, D. T.; Harbison, M. P.; Ford, A. P. D. W. In: Proceedings of the Fifth International Consultation on BPH, Paris, France, World Health Organization: Geneva, Switzerland, 2000, p 550.
13. Piascik M.T., and Perez D.M. J. Pharmacol. Exp. Ther. 298 (2001) 403
14. Smith M.S., Schambra U.B., Wilson K.H., Page S.O., and Schwinn D.A. Mol. Brain Res. 63 (1999) 254
15. Abrams P., Schulman C.C., and Vaage S. Br. J. Urol. 76 (1995) 325
16. Chapple C.R., Wyndaele J.J., Nordling J., Boeminghaus F., Ypma A.F., and Abrams P. Eur. Urol. 29 (1996) 155
17. Lepor H. Urology 51 (1998) 892
18. Lepor H. Urology 51 (1998) 901
19. Andersson K.E., and Wyllie M.G. BJU Int. 92 (2003) 876
20. Rudner X.L., Berkowitz D.E., Booth J.V., Funk B.L., Cozart K.L., D'Amico E.B., El-Moalem H., Page S.O., Richardson C.D., Winters B., Marucci L., and Schwinn D.A. Circulation 100 (1999) 2336
21. Paluchowska M.H., Mokrosz M.J., Bojarski A., Wesolowska A., Borycz J., Charakchieva-Minol S., and Chojnacka-Wojcik E. J. Med. Chem 42 (1999) 4952
22. Raghupathi R.K., Rydelek-Fitzgerald L., Teitler M., and Glennon R.A. J. Med. Chem. 34 (1991) 2633
23. Orjales A., Alonso-Cires L., Labeaga L., and Corcostegui R. J. Med. Chem. 38 (1995) 1273
24. Salman, M.; Yadav, G. C.; Sharma, S.; Kapkoti, G. S.; Chugh, A.; Gupta, J. B.; Anand, N. 2003, WO 2003084928.
25. Salman, M.; Sharma, S.; Yadav, G. C.; Kapkoti, G. S.; Mishra, A.; Gupta, P.; Anand, N.; Chugh, A.; Nanda, K. 2005, WO 2005118537.
26. Kuo G.-H., Prouty C., Murray W.V., Pulito V., Jolliffe L., Cheung P., Varga S., Evangelisto M., and Wang J. J. Med. Chem. 43 (2000) 2183
27. Kuo G.-H., Prouty C., Murray W.V., and Shah R.D. J. Heterocycl. Chem. 38 (2001) 1003
28. 3, TMS) δ 1.36 (d, J = 6 Hz, 6H), 1.42-1.60 (m, 2H), 1.60-1.93 (m, 5H), 2.00-2.58 (m, 4H), 2.65-2.88 (m, 3H), 2.95-3.28 (m, 3H), 4.00-4.20 (m, 1H), 4.50-4.70 (m, 1H), 6.8-7.05 (m, 4H).
29. 1-AR antagonists (Ref. 26) and hence are also expected to have antagonist activity.